Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) has continued
development and standardization of methodologies for biomarkers and has provided an …

Background Mild cognitive impairment (MCI) due to Alzheimer's disease is the symptomatic
predementia phase of Alzheimer's disease dementia, characterised by cognitive and …

Cerebrospinal fluid (CSF) biomarkers based on the core pathological proteins associated
with Alzheimer's disease (AD), ie, amyloid-β (Aβ) and tau protein, are widely regarded as …

Introduction: Biomarkers that reflect pathologic processes affecting neuronal function during
preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug …

We performed a systematic review of studies focusing on the automatic prediction of the
progression of mild cognitive impairment to Alzheimer's disease (AD) dementia, and a …

Background During the last two decades, over 100 proteomics studies have identified a
variety of potential biomarkers in CSF of Alzheimer's (AD) patients. Although several reviews …

Alzheimer's Disease (AD) is the most common cause of dementia, and its characteristic
histopathological hallmarks are neurofibrillary tangles and senile plaques. Among involved …

Alzheimer's disease (AD) is the most common cause of dementia and is characterized by
aggregation of amyloid and tau proteins in the brain. Results from genetic studies suggest …

Alzheimer's disease (AD) is the most common cause of dementia. Biomarkers are required
to identify individuals in the preclinical phase, explain phenotypic diversity, measure …

Objective To determine the key inflammatory pathways that are activated in the peripheral
and CNS compartments at the mild cognitive impairment (MCI) stage of Alzheimer's disease …